Biogen Inc (BIIB)

$132.87 -0.32 (-0.24%)
Market Cap 19.47B
Revenue (ttm) 9.68B
Net Income (ttm) 1.63B
EPS (ttm) N/A
PE Ratio 8.42
Forward PE 8.89
Profit Margin 16.87%
Debt to Equity Ratio 0.27
Volume 633,300
Avg Vol 1,543,308
Day's Range N/A - N/A
Shares Out 146.53M
Stochastic %K 84%
Beta 0.14
Analysts Sell
Price Target $170.14

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar refer...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: (617) 679-2000
Address:
225 Binney Street, Cambridge, United States
theDIOyears
theDIOyears Jul. 3 at 12:09 AM
$BIIB Are we finally in an uptrend? I hope. Biogen (BIIB)'s LEQEMBI, Is currently approved for intravenous infusion administration. The maintenance dose subcutaneous use version that can be administered at home has a tentative regulatory decision date issued by the FDA. It is called the Prescription Drug User Fee Act (PDUFA) , it is on August 31, 2025. Also remember that screening for Alzheimer's disease just got a lot easier because in May 16th 2025 the FDA approve the first and only blood screening test for Alzheimer's. They have earnings on July 31st, 2025. I'm expecting the price to bounce between the upper and lower BOLL bands in the next few weeks. God speed $VRTX $OGN $ABBV $BCRX
0 · Reply
kellysmith1
kellysmith1 Jul. 2 at 6:59 PM
$BIIB $NRSN what announcement….stop it… nothing to see here..
0 · Reply
kellysmith1
kellysmith1 Jul. 2 at 6:58 PM
$BIIB $NRSN announce what???
0 · Reply
funnymoney90210
funnymoney90210 Jul. 2 at 4:43 PM
$NRSN come on $BIIB It's time to announce!
0 · Reply
iQuicky
iQuicky Jul. 2 at 2:03 PM
$BIIB so the up trend is real? okay!
0 · Reply
Ziggy11
Ziggy11 Jul. 2 at 1:44 PM
$LLY $MRK $CRSP $BIIB Time to shift
0 · Reply
Ziggy11
Ziggy11 Jul. 1 at 7:48 PM
$LLY $BIIB $CRSP $REGN Rotation
0 · Reply
ZacksResearch
ZacksResearch Jul. 1 at 4:04 PM
$BIIB initiates late-stage trial for kidney disease treatment Biogen begins dosing in Phase III study for felzartamab, targeting unmet needs in PMN treatment with no current approved therapies. Top-line data expected in 2029. See what this means for Biogen's pipeline here 👉 https://www.zacks.com/commentary/2559740/biogen-begins-phase-iii-felzartamab-study-for-third-kidney-disease?cid=sm-stocktwits-2-2559740-body-550&ADID=SYND_STOCKTWITS_TWEET_2_2559740_BODY_550
0 · Reply
Crystal_the_methhead
Crystal_the_methhead Jul. 1 at 3:54 PM
$BIIB Three bits of good news from Biogen today to counter their recent bad news. Successful phase 1 results for Salanersen. Phase 3 initiated for felzartamab. Quarterly financial date set for 31st July. Its 7% up at time of post, could be an AH runner.
0 · Reply
ZacksResearch
ZacksResearch Jul. 1 at 2:50 PM
$BIIB starts dosing in Phase III — could this be a game-changer? The study targets primary membranous nephropathy, a challenging kidney disease with no approved therapies yet. Full breakdown of the setup here 👉 https://www.zacks.com/stock/news/2559740/biogen-begins-phase-iii-felzartamab-study-for-third-kidney-disease?cid=sm-stocktwits-2-2559740-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2559740_TEASER
0 · Reply
Latest News on BIIB
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

Jun 30, 2025, 7:30 AM EDT - 5 days ago

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA

Jun 27, 2025, 10:00 AM EDT - 8 days ago

New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

Jun 25, 2025, 7:30 AM EDT - 10 days ago

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

Biogen: Investors Are Missing The Bigger Picture

Jun 22, 2025, 10:27 PM EDT - 12 days ago

Biogen: Investors Are Missing The Bigger Picture

20 companies in the S&P 500 whose investors have gained the greatest rewards from stock buybacks

Jun 18, 2025, 11:13 AM EDT - 17 days ago

20 companies in the S&P 500 whose investors have gained the greatest rewards from stock buybacks

AAPL AIG AMAT AZO BK BKNG C

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

Jun 18, 2025, 7:30 AM EDT - 17 days ago

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity

Jun 12, 2025, 1:00 AM EDT - 23 days ago

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity

Biogen Inc. (BIIB) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

Jun 10, 2025, 1:50 PM EDT - 25 days ago

Biogen Inc. (BIIB) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

Jun 3, 2025, 7:00 AM EDT - 4 weeks ago

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

TRDA

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

May 28, 2025, 12:22 PM EDT - 5 weeks ago

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

AMGN DHR GILD IBB ILMN NVS SDGR

Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies

May 27, 2025, 7:30 AM EDT - 5 weeks ago

Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies

Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet

May 12, 2025, 12:30 PM EDT - 7 weeks ago

Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet

ABBV AMGN BMY GILD JNJ LLY MRK

Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal

May 12, 2025, 1:00 AM EDT - 7 weeks ago

Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal

MRK

Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript

May 1, 2025, 11:38 AM EDT - 2 months ago

Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript

Biogen beats quarterly profit estimates on strong demand for rare disease drugs

May 1, 2025, 6:48 AM EDT - 2 months ago

Biogen beats quarterly profit estimates on strong demand for rare disease drugs

Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?

Apr 25, 2025, 9:15 AM EDT - 2 months ago

Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union

Apr 15, 2025, 7:00 PM EDT - 2 months ago

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union

EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease

Apr 15, 2025, 11:47 AM EDT - 2 months ago

EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease

Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price Tag

Apr 9, 2025, 5:34 AM EDT - 3 months ago

Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price Tag

SAGE

Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease

Apr 2, 2025, 7:30 AM EDT - 3 months ago

Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease

Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.

Mar 27, 2025, 10:22 AM EDT - 3 months ago

Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.

ABBV AMGN BMY GILD IHE JNJ LLY

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

Mar 24, 2025, 7:30 AM EDT - 3 months ago

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

Biogen Inc. (BIIB) Stifel 2025 Virtual CNS Forum Conference (Transcript)

Mar 18, 2025, 2:39 PM EDT - 3 months ago

Biogen Inc. (BIIB) Stifel 2025 Virtual CNS Forum Conference (Transcript)

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Mar 11, 2025, 7:30 AM EDT - 4 months ago

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen Inc. (BIIB) Management presents at Leerink Global Healthcare Conference 2025 (Transcript)

Mar 10, 2025, 6:02 PM EDT - 4 months ago

Biogen Inc. (BIIB) Management presents at Leerink Global Healthcare Conference 2025 (Transcript)

Biogen Inc. (BIIB) CEO Chris Viehbacher presents at TD Cowen 45th Annual Health Care Conference (Transcript)

Mar 3, 2025, 6:29 PM EST - 4 months ago

Biogen Inc. (BIIB) CEO Chris Viehbacher presents at TD Cowen 45th Annual Health Care Conference (Transcript)

EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug

Feb 28, 2025, 7:55 AM EST - 4 months ago

EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug

Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy

Feb 18, 2025, 8:46 AM EST - 4 months ago

Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy

STOK

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Feb 18, 2025, 8:00 AM EST - 4 months ago

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

STOK

Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma

Feb 15, 2025, 5:55 AM EST - 5 months ago

Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma

Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts

Feb 13, 2025, 2:30 PM EST - 5 months ago

Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts

Biogen Analysts Lower Their Forecasts After Q4 Results

Feb 13, 2025, 9:03 AM EST - 5 months ago

Biogen Analysts Lower Their Forecasts After Q4 Results

Biogen Delivers Q4 Beat, Analyst Focuses On Leqembi Expansion, 2025 Outlook

Feb 12, 2025, 3:54 PM EST - 5 months ago

Biogen Delivers Q4 Beat, Analyst Focuses On Leqembi Expansion, 2025 Outlook

Biogen Inc. (BIIB) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 12:41 PM EST - 5 months ago

Biogen Inc. (BIIB) Q4 2024 Earnings Call Transcript

Biogen's stock hit by soft guidance and a decline in sales of MS drugs

Feb 12, 2025, 7:48 AM EST - 5 months ago

Biogen's stock hit by soft guidance and a decline in sales of MS drugs

MS

Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short

Feb 12, 2025, 6:50 AM EST - 5 months ago

Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short

Drugmaker Biogen forecasts 2025 profit below expectations

Feb 12, 2025, 6:47 AM EST - 5 months ago

Drugmaker Biogen forecasts 2025 profit below expectations

Biogen Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Feb 12, 2025, 3:22 AM EST - 5 months ago

Biogen Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Europe to review safety data for Eisai-Biogen Alzheimer's drug

Jan 31, 2025, 6:46 AM EST - 5 months ago

Europe to review safety data for Eisai-Biogen Alzheimer's drug

Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

Jan 31, 2025, 6:30 AM EST - 5 months ago

Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

Sage rejects Biogen's $469 million takeover offer

Jan 27, 2025, 9:28 AM EST - 5 months ago

Sage rejects Biogen's $469 million takeover offer

US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug

Jan 26, 2025, 6:38 PM EST - 5 months ago

US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Jan 26, 2025, 6:33 PM EST - 5 months ago

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

Jan 23, 2025, 7:30 AM EST - 5 months ago

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

Genetic Toxicology Testing Market Research 2024-2034: Increased R&D Activities, Strategic Collaborations, and a Focus on Personalized Therapy Boosts Growth

Jan 23, 2025, 4:05 AM EST - 5 months ago

Genetic Toxicology Testing Market Research 2024-2034: Increased R&D Activities, Strategic Collaborations, and a Focus on Personalized Therapy Boosts Growth

Biogen Inc. (BIIB) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)

Jan 15, 2025, 9:20 AM EST - 6 months ago

Biogen Inc. (BIIB) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)

Biogen CEO sees no burning need for more acquisitions

Jan 14, 2025, 6:01 PM EST - 6 months ago

Biogen CEO sees no burning need for more acquisitions

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Jan 13, 2025, 7:05 PM EST - 6 months ago

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid

Jan 13, 2025, 10:40 AM EST - 6 months ago

Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid

SAGE

Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen

Jan 13, 2025, 7:24 AM EST - 6 months ago

Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen

SAGE

theDIOyears
theDIOyears Jul. 3 at 12:09 AM
$BIIB Are we finally in an uptrend? I hope. Biogen (BIIB)'s LEQEMBI, Is currently approved for intravenous infusion administration. The maintenance dose subcutaneous use version that can be administered at home has a tentative regulatory decision date issued by the FDA. It is called the Prescription Drug User Fee Act (PDUFA) , it is on August 31, 2025. Also remember that screening for Alzheimer's disease just got a lot easier because in May 16th 2025 the FDA approve the first and only blood screening test for Alzheimer's. They have earnings on July 31st, 2025. I'm expecting the price to bounce between the upper and lower BOLL bands in the next few weeks. God speed $VRTX $OGN $ABBV $BCRX
0 · Reply
kellysmith1
kellysmith1 Jul. 2 at 6:59 PM
$BIIB $NRSN what announcement….stop it… nothing to see here..
0 · Reply
kellysmith1
kellysmith1 Jul. 2 at 6:58 PM
$BIIB $NRSN announce what???
0 · Reply
funnymoney90210
funnymoney90210 Jul. 2 at 4:43 PM
$NRSN come on $BIIB It's time to announce!
0 · Reply
iQuicky
iQuicky Jul. 2 at 2:03 PM
$BIIB so the up trend is real? okay!
0 · Reply
Ziggy11
Ziggy11 Jul. 2 at 1:44 PM
$LLY $MRK $CRSP $BIIB Time to shift
0 · Reply
Ziggy11
Ziggy11 Jul. 1 at 7:48 PM
$LLY $BIIB $CRSP $REGN Rotation
0 · Reply
ZacksResearch
ZacksResearch Jul. 1 at 4:04 PM
$BIIB initiates late-stage trial for kidney disease treatment Biogen begins dosing in Phase III study for felzartamab, targeting unmet needs in PMN treatment with no current approved therapies. Top-line data expected in 2029. See what this means for Biogen's pipeline here 👉 https://www.zacks.com/commentary/2559740/biogen-begins-phase-iii-felzartamab-study-for-third-kidney-disease?cid=sm-stocktwits-2-2559740-body-550&ADID=SYND_STOCKTWITS_TWEET_2_2559740_BODY_550
0 · Reply
Crystal_the_methhead
Crystal_the_methhead Jul. 1 at 3:54 PM
$BIIB Three bits of good news from Biogen today to counter their recent bad news. Successful phase 1 results for Salanersen. Phase 3 initiated for felzartamab. Quarterly financial date set for 31st July. Its 7% up at time of post, could be an AH runner.
0 · Reply
ZacksResearch
ZacksResearch Jul. 1 at 2:50 PM
$BIIB starts dosing in Phase III — could this be a game-changer? The study targets primary membranous nephropathy, a challenging kidney disease with no approved therapies yet. Full breakdown of the setup here 👉 https://www.zacks.com/stock/news/2559740/biogen-begins-phase-iii-felzartamab-study-for-third-kidney-disease?cid=sm-stocktwits-2-2559740-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2559740_TEASER
0 · Reply
funnymoney90210
funnymoney90210 Jun. 30 at 2:32 PM
$NRSN $BIIB !!!!!! WE ARE READY FOR THE ANNOUNCEMENT!!!!
0 · Reply
JarvisFlow
JarvisFlow Jun. 30 at 1:10 PM
Wedbush has updated their rating for Biogen ( $BIIB ) to Neutral with a price target of 121.
1 · Reply
BigSqueezeComing
BigSqueezeComing Jun. 30 at 11:55 AM
$BIIB Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy By Biogen Inc. | June 30, 2025, 7:30 AM
0 · Reply
PovertyProfessor
PovertyProfessor Jun. 28 at 2:43 AM
$BIIB should be around 170$
0 · Reply
putsbydayhumanbynight
putsbydayhumanbynight Jun. 27 at 1:43 PM
$INMB people never learn. $BIIB Alzheimers is hard to cure . Scientists have been trying to find a solution, only to be met with failures. Biogen pulled the approved adulhelm drug because it showed little benefits other than costing patients 200k a year.
0 · Reply
JarvisFlow
JarvisFlow Jun. 27 at 1:00 PM
RBC Capital updates rating for Biogen ( $BIIB ) to Outperform, target set at 213.
0 · Reply
Quantumup
Quantumup Jun. 26 at 1:06 PM
Truist reiterated $SRRK Buy-$45 and said, "We hosted a conference call with neurologist Dr. Dusan Roncevic on the potential of apitegromab in SMA." $BHVN $LLY REGN RHHBY $BIIB $NVS Truist additionally said, "KOL noted that apitegromab has potential to address the unmet need of muscle decline which is seen across patients. Data from SAPPHIRE trial is clinically meaningful and supports apitegromab as a combo agent with different approved SMA therapies, as per KOL. He believes the data support a broad label (across ages & ambulatory status) and expects to use drug broadly irrespective of label as long as there are no reimbursement challenges. Broad uptake would be an upside to our estimates given we currently model uptake only in non-ambulatory patients. Reiterate Buy."
0 · Reply
JarvisFlow
JarvisFlow Jun. 26 at 12:00 PM
HC Wainwright & Co. has updated their rating for Biogen ( $BIIB ) to Buy with a price target of 187.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Jun. 26 at 10:33 AM
WATCHLIST JUN 26 2025. $GOOG AI Is Already Speeding Up Discoveries In Chemistry And Physics, But Satya Nadella Says The Real Breakthrough Will Come When We Add Quantum Computing To The Mix $PACB Barclays Maintains Equal-Weight on Pacific Biosciences, Lowers Price Target to $1.5 $ADIL Adial Pharmaceuticals shares are trading higher after the company announced it secured AD04 production agreements with Cambrex and Thermo Fisher Scientific ahead of its New Drug Application submission to the FDA for the treatment of Alcohol Use Disorder. $MRVL Ferric Collaborates With Marvell Technology To Develop Optimized Integrated Power Solutions For Marvell Custom Silicon Platforms $BIIB Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma
0 · Reply
Quantumup
Quantumup Jun. 25 at 6:09 PM
Guggenheim reiterated $LRMR Buy-$26 and said, "Yesterday, we hosted $LRMR mgmt (Carole Ben-Maimon, CEO; Michael Celano, CFO; and Tom Hamilton, Board Member) for an in-person NDR in NY." $BIIB $PTCT Guggenheim additionally said, "Investor focus was on the FDA requirements for nomlabofusp BLA filing and on the company's expectations for the OLE readout in September. Guggenheim provided its Key Takeaways and additional commentary (in image below)⤵️
0 · Reply
forprofit12
forprofit12 Jun. 25 at 3:34 PM
$BIIB added. This is just beat down senselessly
0 · Reply
JackDarwin
JackDarwin Jun. 25 at 1:00 PM
$BIIB Bullish Harami Candlestick Pattern Formed at Downtrend... Wait for Next Day Confirmation Candle
0 · Reply